Games developer tinyBuild seeks to boost £500 million market cap by becoming a media company. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Games developer tinyBuild seeks to boost £500 million market cap by becoming a media company
Games developer tinyBuild seeks to boost £500 million market cap by becoming a media companyView Video
Samarkand Group update the market at the London South East Aquis Special webinar
Samarkand Group update the market at the London South East Aquis Special webinarView Video

Latest Share Chat

TOP NEWS: GlaxoSmithKline And Clover Team Up On Coronavirus Vaccine

Mon, 24th Feb 2020 09:30

(Alliance News) - GlaxoSmithKline PLC and Chinese firm Clover Biopharmaceuticals are to collaborate on a coronavirus vaccine candidate, the two partners announced on Monday.

Clover has entered a research collaboration deal with Glaxo concerning Clover's "protein-based coronavirus vaccine candidate" known as COVID-19 S-Trimer.

Under the deal, Clover said, Glaxo will provide its "pandemic adjuvant system" to Clover to evaluate S-Trimer in preclinical studies. Clover described Glaxo as "a leader in the development of innovative vaccines using different adjuvant systems".

When making a vaccine, an adjuvant can be added to cause an enhanced immune response. In this way, an adjuvant helps provide immunity that is stronger and last for longer compared to just the vaccine alone.

Thomas Breuer, chief medical officer of GSK Vaccines, said: "We are proud to contribute to cutting edge research from scientists at Clover Biopharmaceuticals in China as part of our strategy to make our adjuvant technology available to selected partners who have a promising vaccine candidate against the newly emerged coronavirus."

Breuer added: "The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people."

Shares in Glaxo were down 1.9% at 1,626.00 pence in London on Monday morning.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Related Shares

More News

IP Group investee Apollo Therapeutics completes USD145 million raise

IP Group investee Apollo Therapeutics completes USD145 million raise

17 Jun 21 09:48

BROKER RATINGS: Bank of America double upgrades Morrisons to Buy

BROKER RATINGS: Bank of America double upgrades Morrisons to Buy

17 Jun 21 09:36

Wednesday broker round-up

(Sharecast News) - Pets At Home: Berenberg reiterates buy with a target price of 540p.

16 Jun 21 12:50

Tuesday broker round-up

(Sharecast News) - Page Group: Morgan Stanley downgrades to underweight with a target price of 545p.

15 Jun 21 13:39

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.